202 search results for: Pathophysiology
Can advanced systemic therapies modify pathomechanisms in AD?
Dr. Ramien discusses evidence showing that advanced therapies can modify the mechanisms of atopic dermatitis, improving skin barrier function, normalizing the skin microbiome, and reducing chronic itch.
Can targeting IL-4 and IL-13 have an effect on relieving the burden of atopic and non-atopic comorbidities in AD?
Dr. Amy Paller discusses how targeting IL-4 and IL-13 can improve burden of AD.
Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD
This video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia features Dr. Lisa Weibel presenting how local type 2 inflammation within the skin contributes to epidermal barrier dysfunction, dysbiosis, and neuroimmune dysfunction, leading to the clinical signs and symptoms of AD. Dr. Weibel also reviews how systemic inflammation affects organ systems beyond the skin, and could potentially manifest as atopic and non-atopic comorbidities.
Skin Barrier Dysfunction in AD
In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Lisa Weibel discusses how type 2 inflammation contributes to epidermal barrier dysfunction and AD signs and symptoms.
Dysbiosis, Skin Infections, and Itch
In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Lisa Weibel presents how type 2 inflammation contributes to dysbiosis, skin infections, and itch in patients with AD.
What contributes more to loss of smell in patients with CRSwNP: nasal obstruction or inflammation?
Prof. Mullol discusses the contribution of nasal obstruction and inflammation in loss of smell in patients with CRSwNP
How does a decrease in smell affect sleep disturbance? Is there any direct relation?
Prof. Mullol share his opinion on connection between loss of smell and sleep disorder in patients with CRSwNP.
How often do you suggest to assess sense of smell?
Prof. Mullol highlights the utility of visual analog scale for quick assessment of sense of smell in patients with CRSwNP.
What Do We Know About Type 2 Inflammation in COPD?
Join global expert Dr. Michael Wechsler as he discusses type 2 inflammation in COPD.
The Heterogeneity of Underlying Inflammation in Patients With COPD
Join global expert Professor Ian Pavord as he discusses the heterogeneity of underlying inflammation in patients with COPD.
What Are the Key Inflammatory Processes in Patients with COPD?
Dr. Klaus Rabe, MD, PhD, discusses the key inflammatory processes in patients with COPD and their implications for patient care.
Barrier disruption in AD and the development of environmental and food allergies
Dr. Casale discusses the critical role of barrier disruption in atopic dermatitis
